文献速递神经肌肉病

肌营养不良症与强直性肌营养不良症患者的癌症风险:一项基于登记资料的队列研究

Cancer Risk in Patients With Muscular Dystrophy and Myotonic Dystrophy: A Register-Based Cohort Study.
PubMed 文献 · Neurology · 2024-09-19

该匹配队列研究利用瑞典国家登记资料,纳入1950-2017年出生的肌营养不良症和强直性肌营养不良症患者及匹配对照,评估总体癌症风险及癌症谱。肌营养不良症患者总体癌症风险未增加,但儿童期星形细胞瘤和其他胶质瘤、成年期非甲状腺内分泌癌和胰腺癌风险升高;强直性肌营养不良症患者儿童期脑肿瘤风险升高,成人总体癌症风险升高,且多种特定癌症风险升高。作者认为在考虑改变癌症筛查建议前需进一步研究确认。

要点

  • 肌营养不良症患者总体癌症风险未增加,但儿童期星形细胞瘤和其他胶质瘤及成年期非甲状腺内分泌癌和胰腺癌风险升高。
  • 强直性肌营养不良症成人总体癌症风险升高(HR 2.26,95% CI 1.92-2.66),脑肿瘤、甲状腺癌、非甲状腺内分泌癌、子宫内膜癌、卵巢癌和非黑色素瘤皮肤癌风险亦升高。
  • 作者认为在考虑改变癌症筛查建议前需进一步研究确认癌症风险并描述不同遗传亚型的癌症谱。

核心结论

  • 肌营养不良症患者总体癌症风险未增加,但儿童期星形细胞瘤和其他胶质瘤及成年期非甲状腺内分泌癌和胰腺癌风险升高。
  • 强直性肌营养不良症患者儿童期脑肿瘤风险升高,成人总体癌症风险升高,且多种特定癌症风险升高。
  • 作者认为在考虑改变癌症筛查建议前需进一步研究确认癌症风险并描述不同遗传亚型的癌症谱。

研究设计与样本

  • 匹配队列研究,纳入1950-2017年出生于瑞典的所有肌营养不良症或强直性肌营养不良症患者,并按性别、出生年份和出生县为每个个体匹配50名对照。
  • 共识别肌营养不良症患者2,355例和强直性肌营养不良症患者1,968例。
  • 使用分层Cox比例风险模型估计总体癌症及特定恶性肿瘤的关联。

主要发现

  • 肌营养不良症患者总体癌症风险未增加。
  • 肌营养不良症患者儿童期星形细胞瘤和其他胶质瘤风险升高(HR 8.70,95% CI 3.57-21.20)。
  • 肌营养不良症患者成年期非甲状腺内分泌癌风险升高(HR 2.35,95% CI 1.03-5.34),胰腺癌风险升高(HR 4.33,95% CI 1.55-12.11)。
  • 强直性肌营养不良症患者儿童期脑肿瘤风险升高(HR 3.23,95% CI 1.16-9.01)。
  • 强直性肌营养不良症成人总体癌症风险升高(HR 2.26,95% CI 1.92-2.66),脑肿瘤(HR 10.44,95% CI 7.30-14.95)、甲状腺癌(HR 3.92,95% CI 1.70-9.03)、非甲状腺内分泌癌(HR 7.49,95% CI 4.47-12.56)、子宫内膜癌(HR 8.32,95% CI 4.22-16.40)、卵巢癌(HR 4.00,95% CI 1.60-10.01)和非黑色素瘤皮肤癌(HR 3.27,95% CI 1.32-8.13)风险升高。

临床怎么用

  • 作者认为在考虑改变癌症筛查建议前需进一步研究确认癌症风险并描述不同遗传亚型的癌症谱。

局限性

  • 作者认为在考虑改变癌症筛查建议前需进一步研究确认癌症风险并描述不同遗传亚型的癌症谱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Muscular dystrophies and myotonic disorders are genetic disorders characterized by progressive skeletal muscle degeneration and weakness. Epidemiologic studies have found an increased cancer risk in myotonic dystrophy, although the cancer risk spectrum is poorly characterized. In patients with muscular dystrophy, the cancer risk is uncertain. We aimed to determine the overall cancer risk and cancer risk spectrum in patients with muscular dystrophy and myotonic dystrophy using data from the Swedish National registers. METHODS: We performed a matched cohort study in all patients with muscular dystrophy or myotonic dystrophy born in Sweden 1950-2017 and 50 matched comparisons by sex, year of birth, and birth county per individual. The association with cancer overall and specific malignancies was estimated using stratified Cox proportional hazard models. RESULTS: We identified 2,355 and 1,968 individuals with muscular dystrophy and myotonic dystrophy, respectively. No increased overall cancer risk was found in muscular dystrophy. However, we observed an increased risk of astrocytomas and other gliomas during childhood (hazard ratio [HR] 8.70, 95% CI 3.57-21.20) and nonthyroid endocrine cancer (HR 2.35, 95% CI 1.03-5.34) and pancreatic cancer (HR 4.33, 95% CI 1.55-12.11) in adulthood. In myotonic dystrophy, we found an increased risk of pediatric brain tumors (HR 3.23, 95% CI 1.16-9.01) and an increased overall cancer risk in adults (HR 2.26, CI 1.92.2.66), specifically brain tumors (HR 10.44, 95% CI 7.30-14.95), thyroid (HR 3.92, 95% CI 1.70-9.03), and nonthyroid endocrine cancer (HR 7.49, 95% CI 4.47-12.56), endometrial (HR 8.32, 95% CI 4.22-16.40), ovarian (HR 4.00, 95% CI 1.60-10.01), and nonmelanoma skin cancer (HR 3.27, 95% CI 1.32-8.13). DISCUSSION: Here, we analyze the cancer risk spectrum of patients with muscular dystrophy and myotonic dystrophy. To the best of our knowledge, this is the first report of an increased risk for CNS tumors in childhood and adult nonthyroid endocrine and pancreatic cancer in muscular dystrophy. Furthermore, for myotonic dystrophy, we confirmed previously reported associations with cancer and expanded the cancer spectrum, finding an unreported increased risk for nonthyroid endocrine cancer. Additional studies confirming the cancer risk and delineating the cancer spectrum in different genetic subtypes of muscular dystrophies are warranted before considering altered cancer screening recommendations than for the general population.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Maya-González C, Tettamanti G, Taylan F, et al. Cancer Risk in Patients With Muscular Dystrophy and Myotonic Dystrophy: A Register-Based Cohort Study. Neurology. 2024. PMID: 39298705. doi:10.1212/WNL.0000000000209883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。